The present study addresses the feasibility of potentiating oral tolerance by immunomanipulation, using the murine model of experimental autoimmune uveoretinitis (EAU) induced by immunization with the retinal antigen interphotoreceptor retinoid binding protein (IRBP). Three feedings of 0.2 mg IRBP every other day before immunization did not protect against EAU, whereas a similar regimen of five doses was protective. However, supplementing the nonprotective 3x regimen with as little as one injection of 1,000 U of human recombinant interleukin-2 (IL-2) resulted in disease suppression that was equal to that of the protective 5x regimen. The protective effect was maintained across a range of IL-2 doses and times of administration; none of the IL-2 regimens tested resulted in disease enhancement. Peyer's Patch cells of 3X-fed and IL-2-treated mice showed greatly increased production of TGF-fl, IL-4, and IL-10 compared with animals given the nonprotective 3x regimen and to animals given the protective 5x regimen. We propose that IL-2 treatment enhances protection from EAU at least in part by stimulating production of antiinflammatory cytokines by regulatory cells in Payer's Patches. Moreover, the observed lymphokine production patterns suggest that whereas protection induced by the 3x + IL-2 regimen is likely to involve antiinflammatory cytokines, protection induced by the 5X regimen might involve anergy or deletion of the uveitogenic T cells. These results could have practical implications for use of IL-2 as a safe and effective way of potentiating oral tolerance. (J. Clin. Invest. 1994. 94:1668-1672
Introduction
The phenomenon of oral tolerance has been established in a number of experimental models of autoimmune disease where the ability to alter the immune response in an antigen-specific fashion has important implications for disease treatment. Although induction of tolerance to orally administered antigens has been recognized for a long time, its potential for treatment of autoimmunity and graft rejection has recently generated renewed interest (1) (2) (3) (4) . Oral administration of autoantigens suppresses a variety of experimental autoimmune diseases, including experimental autoimmune encephalomyelitis, (EAE)' collagen and adjuvant-induced arthritis, diabetes in the non-obese diabetic mouse and experimental autoimmune uveoretinitis (EAU) (4) . Encouraging results have been reported in clinical trials that used oral administration of antigen to ameliorate symptoms of multiple sclerosis and arthritis (5, 6 ) and a clinical trial in uveitis is currently ongoing (Nussenblatt, R. B., unpublished data). The uveitis trial is a randomized, double-masked study, in which patients receive purified bovine Retinal Soluble Antigen (S-antigen, also known as arrestin), bovine retinal extract, or placebo. The data compiled from experimental models as well as from the clinical studies suggest that oral tolerance can control not only the induction stage of autoimmunity, but can also modulate an ongoing immune process (3, 4) . Therefore, strategies that might augment the tolerogenic effect of antigen feeding have not only theoretical but also important practical implications.
Two major mechanisms that have been proposed to mediate oral tolerance are anergy and active suppression. Whereas anergy, manifested as functional silencing of effector T cells through a block in 11L-2 production and proliferation in response to antigen, seems to predominate after administration of high doses of antigen, lower doses appear to favor induction of active suppression mediated by regulatory cells secreting antiinflammatory cytokines (7-11 ). Khoury et al. (7, 12) Serial sections (hematoxylin and eosin) were graded in a masked fashion by one of us, who is an ophthalmic pathologist (C. C. Chan). EAU severity was scored on a scale of 0 to 4 in half-point increments using a semiquantitative grading system based on the number, size and type of lesions present (14) .
Measurement of cytokine production. Peyer's Patches (PP) of each animal were removed 21 d after immunization. The cells were cultured in 96-well plates (5 x 10' cells in each 0.2 ml well) with 20 ,g/ml IRBP or with 2.5 /sg/ml ConA in supplemented (15) DME (GIBCO BRL, Gaithersburg, MD) containing 0.5% fresh-frozen mouse serum.
Supernatants were collected for cytokine assays after 24-36 h. TGF-06 was assayed by inhibition of the mink lung carcinoma (CCL-64) cell line proliferation using [3HIthymidine uptake. Total TGF-,6 was detected after heat activation of the supernatants at 800C for 5 min and the active moiety was detected without pretreating the supernatants. IL-2 and IL-4 were assayed on HT2 cells (as [3H]thymidine uptake) using the monoclonal antibodies S4B6 (anti-LL-2) and llBll (anti-IL-4) to neutralize the reciprocal cytokine. IFN-y and IL-10 were measured by ELISA using the antibody pairs obtained from Pharmingen (Fig. 1) . IL-2 treatment given to mice that received the protective 5x feeding regimen did not appear to lower the disease scores any further; if anything, these mice were less well protected than the respective 5x group that did not receive IL-2. The same dose of IL-2 given at the time of IRBP challenge to control animals had no effect on previously with the 5x feeding, the protection achieved was prolonged: eyes harvested 42 d after immunization still showed considerably milder EAU in the 3 x + IL-2 mice (score 0.6±0.5, incidence 3/3) compared to controls (score 3.8±0.3, incidence 5/5). We studied the effect of dosage and timing of the IL-2 administration on induction of protection from EAU (Fig. 2) . A single high dose of 30,000 U of IL-2 given at the time of uveitogenic challenge (day 0) resulted in a similar level of protection as the dose of 1,000 U. Three consecutive doses of 30,000 U each injected at the time of feeding (days -7, -5, and -3) had a protective effect equivalent to that of a single 30,000 U dose given at the time of challenge. In contrast, 30,000 U of IL-2 given 3 or 7 d after IRBP challenge, or 1,000 U given 7 d after challenge, failed to significantly protect from disease, although a distinct trend towards lower scores was apparent. Delayed hypersensitivity responses to IRBP, evaluated 21 d after immunization, closely followed the disease pattern in the various groups (data not shown).
These results indicate that, within the range of doses of IL-2 and IRBP tested here, (a) the best protection from EAU was achieved when the IL-2 treatment was given on, or before, day 0. It remains to be dissected whether the determining factor was temporal proximity to feeding or the timing relative to immunization; (b) the IL-2 treatment is effective across a wide range of doses, as 1,000 U in a single dose and 90,000 U divided into three consecutive doses were equally effective; and (c) the treatment has a wide margin of safety, since there was no enhancement of disease with any dose or timing of IL-2 administration. It is also worth noting, in view of the well known toxic effects of systemically administered IL-2, that the dose capable of potentiating oral tolerance is considerably below the toxicity range reported for mice, rats and humans (18-20).
The mechanism of IL-2-induced potentiation of tolerance appears to involve induction of anti-inflammatory cytokines.
One of the postulated mechanisms of oral tolerance is by antiinflammatory cytokines such as TGF-,/ and IL-4 (7, 8 had identical cytokine profiles to mice that received the nonprotective 3x feeding ( Fig. 3 and unpublished data) . The finding that production of antiinflammatory cytokines was higher across the board in the protected groups, strongly suggests that it had a role in determining the clinical outcome. We interpret these results to mean that a population (s) of regulatory cells was induced by the 3x feeding regimen in the PP. An appropriately timed treatment with IL-2 was able to enhance this regulatory cell population(s) sufficiently to obtain a net protective effect from EAU.
The mechanism of tolerance induced by the 3X-feeding + IL-2 regimen may differ from tolerance induced by the 5x feeding regimen. The amount of IL-4 and (total) TGF-,8 were assayed in supernatants of PP cells from mice orally tolerized to IRBP using the different regimens. EAU scores of these mice are shown in Fig. 1 . As before, PP cells of the protected 3x + IL-2 group produced high amounts of TGF-,l and IL-4. In contrast, PP cells of mice protected by the 5x feeding regimen produced minimal amounts of these cytokines, which was not increased by treatment of the 5x fed mice with IL-2 (Fig. 4) . These findings can be interpreted as indicative of a difference in the mechanism of tolerance induced by these two feeding regimens. We propose that protection from EAU induced by the 3x + 11L-2 regimen involves production of suppressive cytokines, whereas the 5 x feeding regimen, which does not appear to result in suppressive cytokine production even after mechanisms would be more beneficial in the long term from a therapeutic point of view, remains to be determined.
In conclusion, immunomodulation achieved by combining IL-2 treatment with oral administration of antigen could have practical clinical implications as a safe and effective way of potentiating oral tolerance. It is very encouraging that the therapeutic window with respect to both efficacy and safety is extremely broad, and the effective dose is well within the nontoxic range. Other routes of IL-2 administration, i.e., intravenous, subcutaneous, and oral, should be investigated. Future studies with clinical orientation should address the use of IL-2 for potentiation of tolerogenic oral regimens initiated after onset of disease.
